Guides: how compounded GLP-1 pricing, pharmacies, and formulations work
These short reference guides answer the mechanical questions that decide whether a compounded semaglutide or tirzepatide program is safe, lawful, and fairly priced: what 503A and 503B mean, why beyond-use dates matter on prepaid plans, how brand and compounded costs relate, how commitment and shipment schedules hide fees, whether compounded products are FDA approved (they are not), and why vial concentrations make doses non-comparable. Each links to the deeper hub on its topic.
Pharmacy and regulation
503A vs 503B pharmacies
What the two pharmacy pathways mean and why neither is FDA approval.
Beyond-use dates
The expiry rule multi-month prepaid plans don't advertise.
Brand vs compounded cost
How list prices, manufacturer cash-pay, insurance, and compounded pricing relate.
Commitment vs shipment cadence
The plan structure that hides fees, and the four numbers to get in writing.
Is compounded semaglutide FDA approved?
Direct answer with the regulatory basis.
Is compounded tirzepatide FDA approved?
Direct answer with the regulatory basis.
Vials, concentrations & syringe units
Why doses can never be compared across concentrations.
How these guides fit the site
The guides are entry points; the authoritative depth lives on the hubs they link to — the safety guide, pharmacy-verification workflow, pricing hub, and methodology. Several individual guides are currently marked for expansion and medical review before indexing; this hub stays the stable parent for all of them. For the machine-readable data behind every price referenced in a guide, see the public evidence ledger.
Frequently asked questions
Are compounded GLP-1 medications FDA approved?
No. No compounded semaglutide or tirzepatide is FDA approved, in any formulation, and none is a generic of an approved product. FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed. The guides on FDA-approval status explain what compounding law does and doesn't permit.
Does a 503B facility mean the product is FDA approved?
No. 503B registration is a facility status that brings cGMP requirements and FDA inspection — genuine oversight — but it is never product approval. No compounded product is FDA approved regardless of whether it comes from a 503A pharmacy or a 503B outsourcing facility. Verify the specific facility with the verification workflow.
Why do vial concentrations matter for dosing?
Because insulin-syringe "units" measure volume, not medication, the same unit count delivers different milligram doses at different concentrations. When a concentration changes between shipments, an old unit count can significantly over- or under-dose. The vials-and-concentrations guide explains why doses can never be copied across products, and why the prescription label is the only safe instruction source.